Extracellular matrix proteins in the regulation of thrombus formation

Current Opinion in Hematology

Volumn 23, Issue 3, 2016, Pages 280-287

  Wang, Yiming ^a,b   Gallant, Reid C ^a,b   Ni, Heyu ^a,b,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Extracellular matrix; Fibrinogen; Fibronectin; Platelet; Von Willebrand factor

Indexed keywords

COLLAGEN; FIBRIN; FIBRINOGEN; FIBRONECTIN; LAMININ; SCLEROPROTEIN; THROMBOCYTE RECEPTOR; THROMBOSPONDIN 1; VITRONECTIN; VON WILLEBRAND FACTOR;

BLOOD CLOTTING; HEMOSTASIS; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; SUBENDOTHELIUM; THROMBOSIS; ANIMAL; METABOLISM;

ANIMALS; EXTRACELLULAR MATRIX PROTEINS; HEMOSTASIS; HUMANS; THROMBOSIS;

EID: 84957928395     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0000000000000237     Document Type: Review

References (82)

1. Beaulieu LM, Freedman JE. Inhibition of platelet function by the endothelium. In: Michelson AD, editor. Platelets, 3rd ed. London: Academic Press; 2013. pp. 313-342.
2. Ruggeri ZM. Platelets in atherothrombosis. Nat Med 2002; 8:1227-1234.
3. Wang Y, Reheman A, Spring CM, et al. Plasma fibronectin supports hemostasis and regulates thrombosis. J Clin Invest 2014; 124:4281-4293.
4. Hou Y, Carrim N, Wang Y, et al. Platelets in hemostasis and thrombosis: novel mechanisms of fibrinogen-independent platelet aggregation and fibronectinmediated protein wave of hemostasis. J Biomed Res 2015; 29:437-444.
5. Bergmeier W, Hynes RO. Extracellular matrix proteins in hemostasis and thrombosis. Cold Spring Harb Perspect Biol 2011; 4:1-17.
6. Wang Y, Andrews M, Yang Y, et al. Platelets in thrombosis and hemostasis: old topic with new mechanisms. Cardiovasc Hematol Disord Drug Targets 2012; 12:126-132.
7. Gui T, Reheman A, Funkhouser WK, et al. In vivo response to vascular injury in the absence of factor IX: examination in factor IX knockout mice. Thromb Res 2007; 121:225-234.
8. Reheman A, Xu X, Reddy EC, et al. Targeting activated platelets and fibrinolysis: hitting two birds with one stone. Circ Res 2014; 114:1070-1073.
9. Yurchenco PD, Patton BL. Developmental and pathogenic mechanisms of basement membrane assembly. Curr Pharm Des 2009; 15:1277-1294.
10. Halfter W, Candiello J, Hu H, et al. Protein composition and biomechanical properties of in vivo-derived basement membranes. Cell Adh Migr 2013; 7:64-71.
11. Falati S, Gross P, Merrill-Skoloff G, et al. Real-time in vivo imaging of platelets, tissue factor and fibrin during arterial thrombus formation in the mouse. Nat Med 2002; 8:1175-1181.
12. Sakurai Y, Fitch-Tewfik JL, Qiu Y, et al. Platelet geometry sensing spatially regulates α-granule secretion to enable matrix self-deposition. Blood 2015; 126:531-538.
13. Reheman A, Gross P, Yang H, et al. Vitronectin stabilizes thrombi and vessel occlusion but plays a dual role in platelet aggregation. J Thromb Haemost 2005; 3:875-883.
14. Stalker TJ, Traxler EA, Wu J, et al. Hierarchical organization in the hemostatic response and its relationship to the platelet-signaling network. Blood 2013; 121:1875-1885.
15. Ni H, Freedman J. Platelets in hemostasis and thrombosis: role of integrins and their ligands. Transfus Apher Sci 2003; 28:257-264.
16. Savage B, Almus-Jacobs F, Ruggeri ZM. Specific synergy of multiple substrate-receptor interactions in platelet thrombus formation under flow. Cell 1998; 94:657-666.
17. Goto S, Ikeda Y, Saldivar E, et al. Distinct mechanisms of platelet aggregation as a consequence of different shearing flow conditions. J Clin Invest 1998; 101:479-486.
18. Nesbitt WS, Westein E, Tovar-Lopez FJ, et al. A shear gradient-dependent platelet aggregation mechanism drives thrombus formation. Nat Med 2009; 15:665-673.
19. Lei X, Reheman A, Hou Y, et al. Anfibatide, a novel GPIb complex antagonist, inhibits platelet adhesion and thrombus formation in vitro and in vivo in murine models of thrombosis. Thromb Haemost 2014; 111:279-289.
20. Jackson SP. The growing complexity of platelet aggregation. Blood 2007; 109:5087-5095.
21. Plow EF, Meller J, Byzova TV. Integrin function in vascular biology: a view from. Curr Opin Hematol 2014; 21:241-247.
22. Ni H, Denis CV, Subbarao S, et al. Persistence of platelet thrombus formation in arterioles of mice lacking both von Willebrand factor and fibrinogen. J Clin Invest 2000; 106:385-392.
23. Yang H, Reheman A, Chen P, et al. Fibrinogen and von Willebrand factorindependent platelet aggregation in vitro and in vivo. J Thromb Haemost 2006; 4:2230-2237.
24. Reheman A, Yang H, Zhu G, et al. Plasma fibronectin depletion enhances platelet aggregation and thrombus formation in mice lacking fibrinogen and von Willebrand factor. Blood 2009; 113:1809-1817.
25. Dunne E, Spring CM, Reheman A, et al. Cadherin 6 has a functional role in platelet aggregation and thrombus formation. Arterioscler Thromb Vasc Biol 2012; 32:1724-1731.
26. Reheman A, Tasneem S, Ni H, et al. Mice with deleted multimerin 1 and αsynuclein genes have impaired platelet adhesion and impaired thrombus formation that is corrected by multimerin 1. Thromb Res 2010; 125:e177-e183.
27. Wang Y, Carrim N, Ni H. Fibronectin orchestrates thrombosis and hemostasis. Oncotarget 2015; 6:19350-19351.
28. Zheng XL. Structure-function and regulation of ADAMTS-13 protease. J Thromb Haemost 2013; 11 (Suppl 1):11-23.
29. Muia J, Zhu J, Gupta G, et al. Allosteric activation of ADAMTS13 by von Willebrand factor. Proc Natl Acad Sci U S A 2014; 111:18584-18589.
30. Tersteeg C, de Maat S, De Meyer SF, et al. Plasmin cleavage of von Willebrand factor as an emergency bypass for ADAMTS13 deficiency in thrombotic microangiopathy. Circulation 2014; 129:1320-1331.
31. Chen J, Reheman A, Gushiken FC, et al. N-acetylcysteine reduces the size and activity of von Willebrand factor in human plasma and mice. J Clin Invest 2011; 121:593-603.
32. Chen J, Özpolat T, Norby C, et al. N-acetylcysteine treatment in two patients with relapsed thrombotic thrombocytopenic purpura increased ADAMTS13 activity, free thiol concentration in plasma, and inhibited platelet activation. Blood 2015; 126:239-1239.
33. Da Q, Behymer M, Correa JI, et al. Platelet adhesion involves a novel interaction between vimentin and von Willebrand factor under high shear stress. Blood 2014; 123:2715-2721.
34. Gilbert JC, DeFeo-Fraulini T, Hutabarat RM, et al. First-in-human evaluation of anti von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers. Circulation 2007; 116:2678-2686.
35. Xiang Y, Cheng J, Wang D, et al. Hyperglycemia repression of miR-24 coordinately upregulates endothelial cell expression and secretion of von Willebrand factor. Blood 2015; 125:3377-3387.
36. Chung DW, Chen J, Ling M, et al. High density lipoprotein modulates thrombosis by preventing von Willebrand factor self-association and subsequent platelet adhesion. Blood 2015. [Epub ahead of print]
37. Farndale RW, Sixma JJ, Barnes MJ, et al. The role of collagen in thrombosis and hemostasis. J Thromb Haemost 2004; 2:561-573.
38. Guglielmini G, Appolloni V, Momi S, et al. Matrix metalloproteinase-2 enhances platelet deposition on collagen under flow conditions. Thromb Haemost 2015; 115. [Epub ahead of print]
39. Howes JM, Pugh N, Knauper V, et al. Modified platelet deposition on MMP-13 digested collagen I. J Thromb Haemost 2015; 13:2253-2259.
40. Nieswandt B, Watson SP. Platelet-collagen interaction: is GPVI the central receptor? Blood 2003; 102:449-461.
41. Nieswandt B, Brakebusch C, Bergmeier W, et al. Glycoprotein VI but not α2β1 integrin is essential for platelet interaction with collagen. EMBO J 2001; 20:2120-2130.
42. Inoue O, Suzuki-Inoue K, McCarty OJ, et al. Laminin stimulates spreading of platelets through integrin α6β1-dependent activation of GPVI. Blood 2006; 107:1405-1412.
43. Cho J, Mosher DF. Characterization of fibronectin assembly by platelets adherent to adsorbed laminin-111. J Thromb Haemost 2006; 4:943-951.
44. Ni H. Unveiling the new face of fibronectin in thrombosis and hemostasis. J Thromb Haemost 2006; 4:940-942.
45. Neerman-Arbez M. Fibrinogen gene mutations accounting for congenital a fibrinogenemia. Ann N Y Acad Sci 2001; 936:496-508.
46. Ruggeri ZM. Old concepts and new developments in the study of platelet aggregation. J Clin Invest 2000; 105:699-701.
47. Ni H, Papalia JM, Degen JL, et al. Control of thrombus embolization and fibronectin internalization by integrin αIIbβ3 engagement of the fibrinogen gamma chain. Blood 2003; 102:3609-3614.
48. Kasahara K, Kaneda M, Miki T, et al. Clot retraction is mediated by factor XIIIdependent fibrin-αIIbβ3-myosin axis in platelet sphingomyelin-rich membrane rafts. Blood 2013; 122:3340-3348.
49. Zafar H, Li J, David GA III, et al. Activated, but not unactivated, αIIbβ3 can mediate adhesion to fibrinogen lacking the γ chain dodecapeptide. Blood 2015; 126:1035-11035.
50. Massberg S, Enders G, Matos FC, et al. Fibrinogen deposition at the postischemic vessel wall promotes platelet adhesion during ischemia-reperfusion in vivo. Blood 1999; 94:3829-3838.
51. Guadiz G, Sporn LA, Simpson-Haidaris PJ. Thrombin cleavage-independent deposition of fibrinogen in extracellular matrices. Blood 1997; 90:2644-2653.
52. Leiss M, Beckmann K, Giros A, et al. The role of integrin binding sites in fibronectin matrix assembly in vivo. Curr Opin Cell Biol 2008; 20:502-507.
53. Zerlauth G, Wolf G. Plasma fibronectin as a marker for cancer and other diseases. Am J Med 1984; 77:685-689.
54. Tomasini-Johansson B, Mosher DF. Plasma fibronectin concentration in inbred mouse strains. Thromb Haemost 2009; 102:1278-1280.
55. Zhai Z, Wu J, Xu X, et al. Fibrinogen controls human platelet fibronectin internalization and cell-surface retention. J Thromb Haemost 2007; 5:1740-1746.
56. Xu X, Wu J, Zhai Z, et al. A novel fibrinogen Bβ chain frameshift mutation in a patient with severe congenital hypofibrinogenaemia. Thromb Haemost 2006; 95:931-935.
57. Ni H, Yuen PS, Papalia JM, et al. Plasma fibronectin promotes thrombus growth and stability in injured arterioles. Proc Natl Acad Sci U S A 2003; 100:2415-2419.
58. Maurer E, Schaff M, Receveur N, et al. Fibrillar cellular fibronectin supports efficient platelet function and procoagulant activity. Thromb Haemost 2015; 114:1175-1188.
59. Wang Y, Ni H. Fibronectin: extra domain brings extra risk? Blood 2015; 125:3043-3044.
60. Dhanesha N, Ahmad A, Prakash P, et al. Genetic ablation of extra domain A of fibronectin in hypercholesterolemic mice improves stroke outcome by reducing thrombo-inflammation. Circulation 2015; 132:2237-2247.
61. Doddapattar P, Gandhi C, Prakash P, et al. Fibronectin splicing variants containing extra domain a promote atherosclerosis in mice through toll-like receptor 4. Arterioscler Thromb Vasc Biol 2015; 35:2391-2400.
62. Prakash P, Kulkarni PP, Lentz SR, et al. Cellular fibronectin containing extra domain A promotes arterial thrombosis in mice through platelet Toll-like receptor 4. Blood 2015; 125:3164-3172.
63. Plow EF. Vitronectin: back into the spotlight. J Thromb Haemost 2005; 3:873-874.
64. Wu YP, Bloemendal HJ, Voest EE, et al. Fibrin-incorporated vitronectin is involved in platelet adhesion and thrombus formation through homotypic interactions with platelet-associated vitronectin. Blood 2004; 104:1034-1041.
65. Furie BC. Thiol isomerases as potential regulators controlling the initiation of thrombus formation. Proceedings of the American Society of Hematology 57th Annual Meeting & Exposition; 5-8 December 2015; Orlando; 2015.
66. Jasuja R, Passam FH, Kennedy DR, et al. Protein disulfide isomerase inhibitors constitute a new class of antithrombotic agents. J Clin Invest 2012; 122:2104-2113.
67. Furie B, Flaumenhaft R. Thiol isomerases in thrombus formation. Circ Res 2014; 114:1162-1173.
68. Bonnefoy A, Moura R, Hoylaerts MF. The evolving role of thrombospondin-1 in hemostasis and vascular biology. Cell Mol Life Sci 2008; 65:713-727.
69. Bonnefoy A, Daenens K, Feys HB, et al. Thrombospondin-1 controls vascular platelet recruitment and thrombus adherence in mice by protecting (sub)-endothelial VWF from cleavage by ADAMTS13. Blood 2006; 107:955-964.
70. Kuijpers MJ, de Witt S, Nergiz-Unal R, et al. Supporting roles of platelet thrombospondin-1 and CD36 in thrombus formation on collagen. Arterioscler Thromb Vasc Biol 2014; 34:1187-1192.
71. Prakash P, Kulkarni PP, Chauhan AK. Thrombospondin 1 requires von Willebrand factor to modulate arterial thrombosis in mice. Blood 2015; 125:399-406.
72. Stenina OI, Plow EF. Counterbalancing forces: what is thrombospondin-1 doing in atherosclerotic lesions? Circ Res 2008; 103:1053-1055.
73. Narizhneva NV, Razorenova OV, Podrez EA, et al. Thrombospondin-1 upregulates expression of cell adhesion molecules and promotes monocyte binding to endothelium. FASEB J 2005; 19:1158-1160.
74. Moura R, Tjwa M, Vandervoort P, et al. Thrombospondin-1 deficiency accelerates atherosclerotic plaque maturation in ApoE-/- mice. Circ Res 2008; 103:1181-1189.
75. von Bruhl ML, Stark K, Steinhart A, et al. Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo. J Exp Med 2012; 209:819-835.
76. Byrnes JR, Duval C, Wang Y, et al. Factor XIIIa-dependent retention of red blood cells in clots is mediated by fibrin α-chain crosslinking. Blood 2015; 126:1940-1948.
77. Vercellotti GM, McCarthy J, Furcht LT, et al. Inflamed fibronectin: an altered fibronectin enhances neutrophil adhesion. Blood 1983; 62:1063-1069.
78. Lishko VK, Yakubenko VP, Ugarova TP. The interplay between integrins αMβ2 and α5β1 during cell migration to fibronectin. Exp Cell Res 2003; 283:116-126.
79. Galkina SI, Sud'ina GF, Klein T. Metabolic regulation of neutrophil spreading, membrane tubulovesicular extensions (cytonemes) formation and intracellular pH upon adhesion to fibronectin. Exp Cell Res 2006; 312:2568-2579.
80. Mou Y, Ni H, Wilkins JA. The selective inhibition of β1 and β7 integrin-mediated lymphocyte adhesion by bacitracin. J Immunol 1998; 161:6323-6329.
81. Ni H, Wilkins JA. Localisation of a novel adhesion blocking epitope on the human β1 integrin chain. Cell Adhes Commun 1998; 5:257-271.
82. Brill A, Fuchs TA, Savchenko A, et al. Neutrophil extracellular traps promote deep vein thrombosis in mice. J Thromb Haemost 2012; 10:136-144.